Stemina Biomarker Discovery is a metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. Stemina’s cell based assays arise from the strategic convergence of two cutting edge technologies: human embryonic stem (hES) cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells and induced pluripotent stem cells (iPS cells), in response to drugs, injury or disease. Stemina opened its state-of-the-art facilities for hES cell culture and mass spectrometry in Madison Wisconsin on November 1, 2007.